Cagrilintide 10mg (Disposable pen)

Cagrilintide 10mg (Disposable pen)



🧬 Cagrilintide – Long-Acting Amylin Analog for Appetite Regulation & Weight Loss Research

Synonyms: AM833, Long-Acting Amylin Receptor Agonist
CAS Number: 1415456-99-3
Sequence: Modified 37-amino acid peptide with disulfide bridge
Molecular Weight: ~4409.0 Da
Form: Pre-filled 10mg injectable pen
Purity: ≥98% (HPLC)
Research Use Only. Not for human consumption.

---

Description:
Cagrilintide is a synthetic, long-acting analog of amylin, a hormone co-secreted with insulin by pancreatic β-cells. It binds to amylin and calcitonin receptors in the brain, particularly in the area postrema and hypothalamus, where it modulates satiety, gastric emptying, and energy intake. The 10mg pre-filled pen format provides precise, once-weekly administration, ideal for long-term metabolic research protocols and combination studies with GLP-1 receptor agonists.

---

⚙️ Mechanism of Action:

Cagrilintide mimics the physiological effects of endogenous amylin but with enhanced stability and extended half-life. It:

• Promotes satiety by activating amylin receptors in the CNS
• Slows gastric emptying, prolonging postprandial fullness
• Reduces food intake without stimulating reward pathways
• Suppresses glucagon secretion, contributing to glycemic control


Its non-incretin mechanism makes it a valuable adjunct in multi-pathway metabolic research.

---

📈 Research Applications:

Cagrilintide is under investigation in preclinical and clinical models for:

• Obesity and appetite regulation
• Type 2 diabetes and glycemic control
• Combination therapy with GLP-1 agonists (e.g., semaglutide, tirzepatide)
• Cardiometabolic risk reduction
• Neuroendocrine signaling and satiety modeling


In Phase 2 trials, Cagrilintide monotherapy achieved up to 10.8% body weight reduction over 26 weeks, with enhanced results when combined with semaglutide.

---

🧪 Dosing & Handling (Preclinical):

• Formulation: 10mg pre-filled pen
• Half-life: ~7–8 days (supports once-weekly administration)
• Storage: Refrigerate at 2–8°C; protect from light
• Administration: Subcutaneous injection; rotate sites weekly
• Cycle: 12–24 weeks typical for metabolic remodeling studies


---

📦 Packaging & Storage:

Supplied as a sterile, pre-filled 10mg pen for subcutaneous administration. Storage: Refrigerate at 2–8°C. Do not freeze. Use aseptic technique. For research use only.

SKU: CAG-10MG-PEN-DSP
£95.00
5 left